Skip to main content
Equibles
SMMT logo

SMMT · Summit Therapeutics Inc. · Metrics

Track SMMT — free

Use SMMT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SMMT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.10 -0.23 (-1.50%) Q2 2026 earnings call transcript
Russell 1000 member Rebalance outlook locked
Going-concern doubt — flagged Jul 23, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Jul 23, 2026
Market Cap
$11.85B
Shares
797.75M
Volume · Oct 28 95.2K Avg daily vol (3M) 6.06M

SMMT metrics

69 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$15.33
Market cap
$11.85B

Price action

20 metrics
Price change (1W)
-4.7%
Price change (30D)
-1.0%
Price change (3M)
+22.2%
Price change (6M)
-27.9%
Price change (YTD)
-12.3%
Price change (1Y)
-21.2%
Trailing year
Price change (5Y)
+197.7%
52-week high
$26.38
52-week low
$12.43
Change from 52-week high
-41.9%
Change from 52-week low
+23.3%
Annualized volatility
71.4%
Annualized volatility (3M)
69.7%
Beta
1.7
RSI (14D)
45.9
Price vs SMA 50
-3.4%
Price vs SMA 200
-5.3%
Avg volume (3M)
6.06M
Relative volume
0.8
Average dollar volume
$94.52M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
797.75M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
18.8
reciprocal yield 5.3%
FCF yield
-3.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-23

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$226.00M
Net income (TTM)
−$856.09M
Trailing 12 months
Diluted EPS (TTM)
$-1.11
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.31
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.12
Operating cash flow per diluted share (TTM)
$-0.60
Free cash flow per diluted share (TTM)
$-0.60
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.74
Stock compensation per diluted share (TTM)
$0.50
Book value per share
$0.85

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-135.9%
Return on assets
-113.8%
Debt / equity
0.0
Current ratio
7.0
EBITDA (TTM)
—
Free cash flow (TTM)
−$459.82M
Quick ratio
7.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$690.68M
Latest balance sheet
Cash & equivalents
$419.37M
Total assets
$752.18M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$458.43M
Capital expenditures (TTM)
$1.39M
R&D (TTM)
$568.74M
SG&A (TTM)
—
Stock compensation (TTM)
$384.04M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
248
13F filer change QoQ
+22
Institutional ownership
17.9%
Conviction holders (share of 13F filers)
0.4%
Crowding (high-turnover and private-fund holders)
8.3%
Private-fund adviser ownership
7.9%
Active holders' share change QoQ
+8.9%
Holder tenure
10.0
Price vs estimated holder cost
+5.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.4%

Short interest

3 metrics
Short interest
5.1%
Latest settlement · 7.0 days to cover
Days to cover
7.0d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1599298 CUSIP 86627T108 13F (30d) 48 filings 48 filers Visit website Investor relations